全文获取类型
收费全文 | 1074篇 |
免费 | 87篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 64篇 |
妇产科学 | 10篇 |
基础医学 | 114篇 |
口腔科学 | 31篇 |
临床医学 | 183篇 |
内科学 | 226篇 |
皮肤病学 | 14篇 |
神经病学 | 49篇 |
特种医学 | 242篇 |
外科学 | 72篇 |
综合类 | 22篇 |
预防医学 | 44篇 |
眼科学 | 7篇 |
药学 | 44篇 |
中国医学 | 5篇 |
肿瘤学 | 37篇 |
出版年
2023年 | 8篇 |
2022年 | 2篇 |
2021年 | 11篇 |
2020年 | 6篇 |
2019年 | 7篇 |
2018年 | 23篇 |
2017年 | 16篇 |
2016年 | 23篇 |
2015年 | 22篇 |
2014年 | 27篇 |
2013年 | 25篇 |
2012年 | 23篇 |
2011年 | 25篇 |
2010年 | 43篇 |
2009年 | 57篇 |
2008年 | 34篇 |
2007年 | 18篇 |
2006年 | 19篇 |
2005年 | 9篇 |
2004年 | 11篇 |
2003年 | 27篇 |
2002年 | 20篇 |
2001年 | 22篇 |
2000年 | 14篇 |
1999年 | 19篇 |
1998年 | 52篇 |
1997年 | 56篇 |
1996年 | 64篇 |
1995年 | 48篇 |
1994年 | 44篇 |
1993年 | 47篇 |
1992年 | 17篇 |
1991年 | 8篇 |
1990年 | 16篇 |
1989年 | 37篇 |
1988年 | 33篇 |
1987年 | 34篇 |
1986年 | 37篇 |
1985年 | 25篇 |
1984年 | 15篇 |
1983年 | 12篇 |
1982年 | 24篇 |
1981年 | 15篇 |
1980年 | 10篇 |
1979年 | 4篇 |
1978年 | 10篇 |
1977年 | 13篇 |
1976年 | 12篇 |
1975年 | 14篇 |
1974年 | 4篇 |
排序方式: 共有1168条查询结果,搜索用时 109 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
Corinna S. Bowser Jean Kaye Rauno O. Joks Cascy-Arnoux Charlot H. Jack Moallem 《Pediatric allergy and immunology》2007,18(4):298-303
Elevated serum immunoglobulin E (IgE) and increased prevalence of atopy is reported in patients infected with human immunodeficiency virus (HIV). The elevated serum IgE may be attributed to polyclonal stimulation of B cells or IgE production against allergens, viruses, fungi and bacteria. This study investigates the prevalence of atopy in perinatally HIV-infected children, and the relationships between serum IgE (and other serum immunoglobulins) with atopy, CD4+ cell count and HIV-disease stage. Serum immunoglobulin levels, epicutaneous skin test for common aeroallergens, clinical Centers for Disease Control and Prevention (CDC) classification, CD4+ cell counts and allergy history were extracted from the charts of perinatally HIV-infected children on highly active antiretroviral therapy. The prevalence of atopy (52%) and the pattern of aeroallergen sensitivity were comparable with the US pediatric population. Serum IgE levels did not correlate with clinical disease stage. However, in non-atopic patients, serum IgE levels increased with disease progression (p = 0.02). There was an inverse relationship between the prevalence of elevated serum IgE levels and atopy with progression of disease (p = 0.019). Serum IgE did not correlate with atopy, CD4+ cell count, or duration of HIV infection or levels of serum immunoglobulins. This is the first study to show no increased prevalence of atopy in perinatally HIV-infected children compared with the general population. In advanced stages of HIV, elevated serum IgE may be specific for antigens other than those known as allergens. 相似文献
10.